Research programme: MOSPD2 therapeutics - VBL Therapeutics

Drug Profile

Research programme: MOSPD2 therapeutics - VBL Therapeutics

Alternative Names: VB-600 series

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VBL Therapeutics
  • Class Anti-inflammatories; Antibodies; Antineoplastics; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 05 Jun 2018 Preclinical trials in Inflammation in Israel before June 2018
  • 05 Jun 2018 VBL Therapeutics announces intention to submit IND for Cancer and Inflammation by year-end 2019
  • 16 Apr 2018 Updated pharmacodynamics data from a preclinical study in Cancer released by VBL Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top